Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.62 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443637 | 0.82 | HRH3 (0.56) | HRH3PLGPLAUALDH1A1CYP2A6 | |
| SCHEMBL3239367 | 0.80 | HRH3 (0.60) | HRH3CHRNA7KDM4EALDH1A1 | |
| SCHEMBL2218073 | 0.78 | HRH3 (0.98) | HRH3 | |
| SCHEMBL2218391 | 0.77 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3247741 | 0.77 | HRH3 (0.57) | HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL3236061 | 0.77 | KDM4E (0.58) | HRH3CHRNA7KDM4E | |
| SCHEMBL3240701 | 0.77 | HRH3 (0.57) | HRH3GPR183CHRNA7KDM4EALDH1A1 | |
| Fluorobenzene SCHEMBL27517444 | 0.77 | RAB9A (0.50) | HRH3PLGPLAUKDM4EALDH1A1 | |
| SCHEMBL3245572 | 0.77 | HRH3 (0.57) | HRH3CHRNA7KDM4EALDH1A1 | |
| SCHEMBL2217841 | 0.76 | AVPR1A (0.58) | HRH3PLGPLAUKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-07-21 | — | — | US | disclosed |
| CN-101679249-A | As histamine H 3The indoles of receptor modulators and benzothienyl compounds | JANSSEN PHARMACEUTICA NV | 2010-03-24 | — | — | CN | disclosed |
| EP-2125720-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008109333-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178062-A1 | INDOLE AND BENZOTHIOPHENE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885PLG 4882/4885PLAU 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.